![vaughns blood pressure chart vaughns blood pressure chart](https://www.27beaumontstreet.co.uk/media/content/images/bp-range-chart.jpg)
Despite this, half of the world's population remains at risk of infection, with an estimated 225 million cases occurring in 2009, resulting in an estimated 781,000 deaths. Significant advances have been made recently in the control of malaria, , with reductions in the incidence and prevalence of infection as well as in malaria-associated mortality.
![vaughns blood pressure chart vaughns blood pressure chart](https://image.slidesharecdn.com/highbloodpressure-120303130433-phpapp02/95/high-blood-pressure-1-728.jpg)
This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. Three of the authors (PG, SE and ND) are employed by Q-Pharm Pty Ltd, Brisbane, Australia. The funder therefore had a role in study design, data collection and analysis, decision to publish, and preparation of the manuscript.Ĭompeting interests: Three of the authors (SD, JM and AJH) are employees of the Medicines for Malaria Venture. Three of the authors (SD, JM and AJH) are employees of the funder. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.įunding: This work was funded by Medicines for Malaria, a non-profit organization whose mission is to advance antimalarial drug development. Received: ApAccepted: JPublished: August 22, 2011Ĭopyright: © 2011 McCarthy et al. PLoS ONE 6(8):Įditor: Lorenz von Seidlein, Menzies School of Health Research, Australia
Vaughns blood pressure chart trial#
(2011) A Pilot Randomised Trial of Induced Blood-Stage Plasmodium falciparum Infections in Healthy Volunteers for Testing Efficacy of New Antimalarial Drugs. In the second and third cohorts, 13 volunteers received 1,800 BSP, with all reaching the target parasitemia before receiving treatment (A/L, n = 6 A/P, n = 7) The study demonstrated safety in the 19 volunteers tested, and a significant difference in the clearance kinetics of parasitemia between the drugs in the 13 evaluable subjects, with mean parasite reduction ratios of 759 for A/L and 17 for A/P (95% CI 120–4786 and 7–40 respectively p<0.01).Ĭitation: McCarthy JS, Sekuloski S, Griffin PM, Elliott S, Douglas N, Peatey C, et al. In the first cohort (n = 6) where volunteers received ∼360 BSP, none reached the target parasitemia of 1,000 before the day designated for antimalarial treatment (day 6). Volunteers were randomly allocated to treatment with either of two licensed antimalarial drug combinations, artemether–lumefantrine (A/L) or atovaquone-proguanil (A/P). A prospective, unblinded, Phase IIa trial was undertaken in 19 healthy, malaria-naïve, male adult volunteers who were infected with BSP and followed with careful clinical and laboratory observation, including a sensitive, quantitative malaria PCR assay.